@article{130ad8b1eb9e4e338344dfb97a7ddfa5,
title = "Epidemiological evidence that common HPV types may be common because of their ability to evade immune surveillance: Results from the Women's Interagency HIV study",
abstract = "Infection by human papillomavirus (HPV) type 16, the most oncogenic HPV type, was found to be the least affected by HIV-status and CD4 count of any of the approximately 13 oncogenic HPV types. This relative independence from host immune status has been interpreted as evidence that HPV16 may have an innate ability to avoid the effects of immunosurveillance. However, the impact of immune status on other individual HPV types has not been carefully assessed. We studied type-specific HPV infection in a cohort of 2,470 HIV-positive (HIV[+]) and 895 HIV-negative (HIV[−]) women. Semi-annually collected cervicovaginal lavages were tested for >40 HPV types. HPV type-specific prevalence ratios (PRs), incidence and clearance hazard ratios (HRs), were calculated by contrasting HPV types detected in HIV[+] women with CD4 < 200 to HIV[−] women. HPV71 and HPV16 prevalence had the weakest associations with HIV-status/CD4 count of any HPV, according to PRs. No correlations between PRs and HPV phylogeny or oncogenicity were observed. Instead, higher HPV type-specific prevalence in HIV[−] women correlated with lower PRs (ρ = −0.59; p = 0.0001). An alternative (quadratic model) statistical approach (PHIV+ = a*PHIV− + b*PHIV− 2; R2 = 0.894) found similar associations (p = 0.0005). In summary, the most prevalent HPV types in HIV[−] women were the types most independent from host immune status. These results suggest that common HPV types in HIV[−] women may have a greater ability to avoid immune surveillance than other types, which may help explain why they are common.",
author = "Castle, {Philip E.} and Burk, {Robert D.} and Massad, {Leslie S.} and Eltoum, {Isam Eldin} and Hall, {Charles B.} and Hessol, {Nancy A.} and Kathryn Anastos and Xianhong Xie and Howard Minkoff and Xiaonan Xue and Gypsyamber D'Souza and Lisa Flowers and Christine Colie and Lisa Rahangdale and Fischl, {Margaret A.} and Palefsky, {Joel M.} and Strickler, {Howard D.}",
note = "Funding Information: HPV testing and the current analyses were supported by the National Cancer Institute (NCI) (grant numbers R01‐CA‐230331, R01‐CA‐085178 and R01‐CA‐174634 to H. D. S. and P30‐CA‐013330, P30‐AI24414). Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH). WIHS (Principal Investigators): UAB‐MS WIHS (Michael Saag, Mirjam‐Colette Kempf and Deborah Konkle‐Parker), U01‐AI‐103401; Atlanta WIHS (Ighovwerha Ofotokun and Gina Wingood), U01‐AI‐103408; Bronx WIHS (Kathryn Anastos), U01‐AI‐035004; Brooklyn WIHS (Howard Minkoff and Deborah Gustafson), U01‐AI‐031834; Chicago WIHS (Mardge Cohen and Audrey French), U01‐AI‐034993; Metropolitan Washington WIHS (Seble Kassaye), U01‐AI‐034994; Miami WIHS (Margaret Fischl and Lisa Metsch), U01‐AI‐103397; UNC WIHS (Adaora Adimora), U01‐AI‐103390; Connie Wofsy Women's HIV Study, Northern California (Ruth Greenblatt, Bradley Aouizerat and Phyllis Tien), U01‐AI‐034989; WIHS Data Management and Analysis Center (Stephen Gange and Elizabeth Golub), U01‐AI‐042590; Southern California WIHS (Joel Milam), U01‐HD‐032632 (WIHS I–WIHS IV). The WIHS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional cofunding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH). Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Deafness and other Communication Disorders (NIDCD) and the NIH Office of Research on Women's Health. WIHS data collection is also supported by UL1‐TR000004 (UCSF CTSA) and UL1‐TR000454 (Atlanta CTSA). Funding Information: HPV testing and the current analyses were supported by the National Cancer Institute (NCI) (grant numbers R01-CA-230331, R01-CA-085178 and R01-CA-174634 to H. D. S. and P30-CA-013330, P30-AI24414). Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH). WIHS (Principal Investigators): UAB-MS WIHS (Michael Saag, Mirjam-Colette Kempf and Deborah Konkle-Parker), U01-AI-103401; Atlanta WIHS (Ighovwerha Ofotokun and Gina Wingood), U01-AI-103408; Bronx WIHS (Kathryn Anastos), U01-AI-035004; Brooklyn WIHS (Howard Minkoff and Deborah Gustafson), U01-AI-031834; Chicago WIHS (Mardge Cohen and Audrey French), U01-AI-034993; Metropolitan Washington WIHS (Seble Kassaye), U01-AI-034994; Miami WIHS (Margaret Fischl and Lisa Metsch), U01-AI-103397; UNC WIHS (Adaora Adimora), U01-AI-103390; Connie Wofsy Women's HIV Study, Northern California (Ruth Greenblatt, Bradley Aouizerat and Phyllis Tien), U01-AI-034989; WIHS Data Management and Analysis Center (Stephen Gange and Elizabeth Golub), U01-AI-042590; Southern California WIHS (Joel Milam), U01-HD-032632 (WIHS I?WIHS IV). The WIHS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional cofunding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH). Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Deafness and other Communication Disorders (NIDCD) and the NIH Office of Research on Women's Health. WIHS data collection is also supported by UL1-TR000004 (UCSF CTSA) and UL1-TR000454 (Atlanta CTSA). Funding Information: PEC has received commercial HPV tests for research at a reduced or no cost from Roche, Cepheid, BD and Arbor Vita Corporation. JMP has been compensated financially as a member of a Merck data and safety monitoring board for HPV vaccines; as a consultant for Vir Biotechnologies received fees and stock options; Antiva Biosences provided grant support; with Ubiome participated in a scientific advisory board and received stock options; with Vaccitech participated in a scientific advisory board and received stock options; with Jannsen Pharmaceuticals was an invited speaker. KA has received grant funding from several institutes at NIH. HDS has received free‐blinded testing using HPV E6/E7 protein assays by Arbor Vista, p16/Ki67 cytology by MTM Laboratories/Ventura–Roche, and MCM‐2/TOP2A cytology by BD Diagnostics. Publisher Copyright: {\textcopyright} 2019 UICC",
year = "2020",
month = jun,
day = "15",
doi = "10.1002/ijc.32693",
language = "English",
volume = "146",
pages = "3320--3328",
journal = "International Journal of Cancer",
issn = "0020-7136",
number = "12",
}